PSNL:NASDAQPersonalis, Inc. Analysis
Data as of 2026-06-21 - not real-time
Latest Price
Risk Level: High
Executive Summary
Personalis, Inc. trades at $10.54, comfortably above its 20‑day ($10.09), 50‑day ($7.76) and 200‑day ($8.05) simple moving averages, indicating short‑term price strength, yet the MACD histogram is negative and the MACD line sits below its signal, flagging bearish momentum. The RSI of 62 reinforces moderate upside pressure without being overbought, while decreasing volume and a 30‑day volatility of ~90% signal a fragile rally. The stock’s beta (>3) and a max drawdown of –55% underscore extreme sensitivity to market swings, and the current price sits midway between a clear support level at $7.70 and resistance near $12.53. On the fundamentals side, the company posts negative gross (13.7%) and operating margins (‑2.1%), a trailing EPS of –$1.02, and a forward PE of –11.8, reflecting ongoing loss generation. Despite the losses, a strong cash pile of $233 M versus $38.8 M of debt provides a solid liquidity cushion, though free cash flow remains deeply negative. The diagnostics sector faces high regulatory scrutiny, and the “Extreme Greed” market sentiment (fear‑greed index 91) may be inflating the price beyond intrinsic value. Overall, the blend of bullish technical positioning, deteriorating cash‑flow fundamentals, and heightened volatility suggests caution pending a clear earnings or partnership catalyst.
Market Outlook
Short Term
< 1 yearKey Factors
- Bearish MACD histogram and signal divergence
- Decreasing volume trend amid high volatility
- Large max drawdown indicating downside vulnerability
Medium Term
1–3 yearsKey Factors
- Substantial cash reserves offsetting debt load
- Potential upside from strategic collaborations in oncology
- Neutral trend direction despite mixed technical signals
Long Term
> 3 yearsKey Factors
- Long‑term growth prospects in cancer genomics and liquid biopsy
- Strategic partnership with Tempus AI expanding market reach
- Industry tailwinds for precision‑medicine diagnostics
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.